Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

194 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
Paukner S, Moran GJ, Sandrock C, File TM Jr, Vidal JE, Waites KB, Gelone SP, Yu K. Paukner S, et al. Among authors: file tm jr. Future Microbiol. 2022 Apr;17(6):397-410. doi: 10.2217/fmb-2021-0276. Epub 2022 Mar 14. Future Microbiol. 2022. PMID: 35285291 Free PMC article. Review.
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S, Goldberg L, Alexander E, Das AF, Heinrich S, Patel P, Moran GJ, Sandrock C, File TM Jr, Vidal JE, Waites KB, Gelone SP, Schranz J. Paukner S, et al. Among authors: file tm jr. J Glob Antimicrob Resist. 2022 Jun;29:434-443. doi: 10.1016/j.jgar.2021.10.021. Epub 2021 Nov 14. J Glob Antimicrob Resist. 2022. PMID: 34788694 Free article. Clinical Trial.
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Cornely OA, File TM Jr, Garrity-Ryan L, Chitra S, Noble R, McGovern PC. Cornely OA, et al. Among authors: file tm jr. Int J Antimicrob Agents. 2021 Feb;57(2):106263. doi: 10.1016/j.ijantimicag.2020.106263. Epub 2020 Dec 14. Int J Antimicrob Agents. 2021. PMID: 33326848 Free article.
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
Huang DB, Magnet S, De Angelis S, Holland TL, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH. Huang DB, et al. Among authors: file tm jr. Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10. Diagn Microbiol Infect Dis. 2019. PMID: 30266399 Free article.
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A. Huang DB, et al. Among authors: file tm jr. Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19. Int J Antimicrob Agents. 2018. PMID: 29783024 Free article. Clinical Trial.
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. Holland TL, et al. Among authors: file tm jr. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530858 Free PMC article. Clinical Trial.
194 results